The cluster of open-market sales by a director and the general counsel, without any offsetting purchases, signals potential insider caution. Monitor for upcoming clinical data readouts or earnings guidance—these sales may precede negative developments.
Price Chart
Executive Summary
Two CRISPR Therapeutics insiders—Director Ali Behbahani and General Counsel James Kasinger—sold a combined $1.41M in open-market sales over a one-week window. The sales represent ~0.43% of the company's market cap, a modest but notable cluster. No 10b5-1 plan is indicated, and the sales are not tax- or vesting-related, suggesting potential bearish conviction ahead of upcoming catalysts or earnings.
Key Financial Metrics
Key Facts
- Director Ali Behbahani sold 13,700 shares at $57.09 for $781K on 2026-09-17.
- General Counsel James Kasinger sold 10,400 shares at $60.24 for $626K on 2026-09-22.
- Total cluster value: $1.41M, representing ~0.43% of market cap.
- Both sales are open-market (code S) with no 10b5-1 plan indication.
- No insider purchases occurred in the same window.
Financial Impact
Total insider selling of $1.41M, or ~0.43% of market cap.
Risk Factors
- Insider sales may be liquidity-driven despite no plan indication.
- No 10b5-1 plan disclosed, but sales could still be pre-arranged.
- Biotech sector volatility could amplify or reverse the signal.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CRSP-1790285748850 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $51.40 (−1.78%) |
Oct 19, 2026 7d ago | 8-K | $49.88 | awaiting T+20 | — | $51.40 (+3.05%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $51.40 (+2.72%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $51.40 (−2.72%) |
Oct 15, 2026 11d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $51.40 (+4.37%) |
Oct 14, 2026 12d ago | 144 | $51.52 | awaiting T+20 | — | $51.40 (−0.23%) |
Oct 6, 2026 20d ago | 144 | $52.35 | awaiting T+20 | — | $51.40 (−1.81%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $51.40 (+5.22%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $51.40 (−10.95%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $51.40 (−3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers